Evidence map›Paper›PMID 40866669›Full record

ArticleJournal of cardiovascular translational research2025

Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention.

Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Diona GjermeniDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. Diona.gjermeni@uniklinik-freiburg.de.ORCID 0000-0003-1711-3901
Hannah VetterDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Sofia SzabóDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Viktoria AnfangDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Carina JuelchDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Stefan LeggewieDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
David HesselbarthDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Markus JäckelDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Daniel DuerschmiedDepartment of Cardiology, Haemostaseology and Medical Intensive Care, Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
Dietmar TrenkDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Dirk WestermannDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Christoph B OlivierDepartment of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg - Bad Krozingen, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet reactivity (PR) in clopidogrel-treated patients undergoing percutaneous coronary syndrome (PCI) associates with ischemic and bleeding risk. The aim was to investigate the association of PR and global hemostasis with this risk in patients with atrial fibrillation (AF) undergoing PCI. TEG was performed on day 1-3 after PCI. 168 patients were included. Mean age was 79 years (IQR 72-82). 101 (60%) patients had high platelet reactivity (HPR). HPR was not associated with the composite outcome of MACE (HR 1.23 [ CI 95% 0.43-3.49], p = 0.700). 33(19.6%) patients had HPR and increased platelet-fibrin clot strength and showed a trend for association with higher ischemic risk (HR 2.83 [CI 95% 0.70-8.06], p = 0.078). Rates of HPR in patients with AF undergoing PCI were high. Neither HPR nor LPR predicted ischemic or bleeding risks. Patients with HPR and increased platelet-fibrin clot strength may be at higher risk for ischemic events.

Indexed as

Atrial FibrillationBlood CoagulationBlood PlateletsClopidogrelCoronary Artery DiseaseFibrinPercutaneous Coronary InterventionPlatelet ActivationPlatelet Aggregation InhibitorsThrombelastographyAgedAged, 80 and overFemaleHemorrhageHumansMaleClopidogrelFibrinPlatelet Aggregation InhibitorsAtrial fibrillationPercutaneous coronary interventionPlatelet aggregationThromboelastography

Identifiers

PMID40866669
PMCPMC12630191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.